摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-甲酰基-3-氯苯并噻吩 | 14006-54-3

中文名称
2-甲酰基-3-氯苯并噻吩
中文别名
3-氯苯并噻吩-2-甲醛
英文名称
3-chloro-1-benzothiophen-2-carbaldehyde
英文别名
3-chlorobenzo[b]thiophene-2-carbaldehyde;3-chloro[1]benzothiophene-2-carbaldehyde;3-chlorobenzothiophene-2-carboxaldehyde;3-chloro-benzothiophene-2-carbaldehyde;3-Chloro-1-benzothiophene-2-carbaldehyde
2-甲酰基-3-氯苯并噻吩化学式
CAS
14006-54-3
化学式
C9H5ClOS
mdl
MFCD00489051
分子量
196.657
InChiKey
UFTPKLPCVLXBQY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    112-113℃ (hexane )
  • 沸点:
    331.1±22.0 °C(Predicted)
  • 密度:
    1.439±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    45.3
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2934999090

SDS

SDS:41aa1fb3659afb6ec1875c8ea046d176
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 3-Chloro-1-benzothiophene-2-carbaldehyde
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H301: Toxic if swallowed
H317: May cause an allergic skin reaction
H319: Causes serious eye irritation
P280: Wear protective gloves/protective clothing/eye protection/face protection
P301+P310: IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

Section 3. Composition/information on ingredients.
Ingredient name: 3-Chloro-1-benzothiophene-2-carbaldehyde
CAS number: 14006-54-3

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C9H5ClOS
Molecular weight: 196.7

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride, sulfur oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
UN Number: UN2811 Class: 6.1 Packing group: III
Proper shipping name: TOXIC SOLIDS, ORGANIC, N.O.S. (3-Chloro-1-benzothiophene-2-carbaldehyde)

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2

反应信息

点击查看最新优质反应信息

文献信息

  • Aminopiperidine quinolines and their azaisosteric analogues with antibacterical activity
    申请人:——
    公开号:US20040038998A1
    公开(公告)日:2004-02-26
    Aminopiperidine derivatives of formula (I) and pharmaceutically acceptable derivatives thereof useful in methods of treatment of bacterial infections in mammals, particularly in man. 1
    氨基哌啶衍生物的公式(I)及其药物可接受的衍生物,用于治疗哺乳动物,特别是人类的细菌感染。
  • [EN] SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS<br/>[FR] COMPOSÉS SPIRO-OXADIAZOLINE EN TANT QU'AGONISTES DES RÉCEPTEURS DE L'ACÉTYLCHOLINE Α-7 NICOTINIQUE
    申请人:FORUM PHARMACEUTICALS INC
    公开号:WO2015066371A1
    公开(公告)日:2015-05-07
    The present invention relates to novel spiro-oxadiazoline compounds that are suitable as agonists or partial agonists of a7-nAChR, and pharmaceutical compositions of the same, methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering a spiro-oxadiazoline cx7-nAChR agonist or partial agonist, to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.
    本发明涉及新型螺环-噁二唑啉化合物,适用作a7-nAChR的激动剂或部分激动剂,以及这些化合物和组合物的制备方法、药物组合物,以及在维持、治疗和/或改善认知功能的方法中使用这些化合物和组合物。具体而言,涉及向需要的患者(例如患有认知缺陷和/或希望增强认知功能的患者)施用螺环-噁二唑啉cx7-nAChR激动剂或部分激动剂的方法,以使其获益。
  • 2,3,4-Substituted cyclopentanones as therapeutic agents
    申请人:Donde Yariv
    公开号:US20060106088A1
    公开(公告)日:2006-05-18
    Disclosed herein are compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof, wherein a dashed line represents the presence or absence of a bond; Y is a carboxylic acid, sulfonic acid, or phosphonic acid functional group; or an amide or ester thereof comprising from 0 to 12 carbon atoms; or Y is hydroxymethyl or an ether thereof comprising from 0 to 12 carbon atoms; or Y is a tetrazolyl functional group; A is —(CH 2 ) 6 —, cis —CH 2 —CH═CH—(CH 2 ) 3 —, or —CH 2 —C≡C—(CH 2 ) 3 — wherein 1 or 2 carbons may be substituted with S or O; B is hydrogen, C 1-6 hydrocarbyl, CN, CO 2 H, or —(CH 2 ) m X(CH 2 ) p H, wherein m is at least 1 and the sum of m and p is from 1 to 5; X is S or O; J is H, CH 3 , or CF 3 ; D is a covalent bond, CH 2 , O, or S; and E is an aromatic heterobicyclic ring system which may have substituents comprising up to 6 non-hydrogen atoms each. Methods, compositions, and medicaments related thereto are also disclosed.
    本文披露了包含以下化合物或其药用可接受盐或前药的化合物,其中虚线代表键的存在或不存在;Y是羧酸、磺酸或膦酸官能团;或者是由0到12个碳原子组成的酰胺或酯;或者Y是羟甲基或由0到12个碳原子组成的醚;或者Y是四唑基官能团;A是—(CH2)6—、顺式—CH2—CH═CH—(CH2)3—或—CH2—C≡C—(CH2)3—其中1或2个碳原子可以被S或O取代;B是氢、C1-6烃基、CN、CO2H或—(CH2)mX(CH2)pH,其中m至少为1,m和p的总和为1到5;X是S或O;J是H、CH3或CF3;D是共价键、CH2、O或S;E是含有最多6个非氢原子的取代基的芳香杂双环环系统。还披露了相关的方法、组合物和药物。
  • 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
    申请人:Allergan, Inc.
    公开号:US20040235958A1
    公开(公告)日:2004-11-25
    The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula I; 1 wherein the dashed line indicates the presence or absence of a bond, the hatched wedge indicates the &agr; (down) configuration, and the solid triangle indicates the &bgr; (up) configuration; B is a single, double, or triple covalent bond; n is 0-6; X is CH 2 , S or O; Y is any pharmaceutically acceptable salt of CO 2 H, or CO 2 R, CONR 2 , CONHCH 2 CH 2 OH, CON(CH 2 CH 2 OH) 2 ,CH 2 OR, P(O)(OR) 2 , CONRSO 2 R, SONR 2 , or 2 R is H, C 1-6 alkyl or C 2-6 alkenyl; R 2 and R 3 are C 1-6 linear alkyl which may be the same or different, and may be bonded to each other such that they form a ring incorporating the carbon to which they are commonly attached; R 4 is hydrogen, R, C(═O)R, or any group that is easily removed under physiological conditions such that R 4 is effectively hydrogen; R 5 is hydrogen or R; R 6 is i) hydrogen; ii) a linear or branched hydrocarbon containing between 1 and 8 carbon atoms, which may contain one or more double or triple bonds, or oxygen or halogen derivatives of said hydrocarbon, wherein 1-3 carbon or hydrogen atoms may be substituted by O or a halogen; or iii) aryloxy, heteroaryloxy, C 3-8 cycloalkyloxy, C 3-8 cycloalkyl, C 6-10 aryl or C 3-10 heteroaryl, wherein one or more carbons is substituted with N, O, or S; and which may contain one or more substituents selected from the group consisting of halogen, trihalomethyl, cyano, nitro, amino, hydroxy, C 6-10 aryl, C 3-10 heteroaryl, aryloxy, heteroaryloxy, C 1-6 alkyl, OR, SR, and SO 2 R. Some of the compounds of the present invention and some of their methods of preparation are also novel an nonobvious.
    本发明提供了一种治疗眼压增高或青光眼的方法,包括向患有眼压增高或青光眼的动物施用一定治疗有效量的一种由通式I表示的化合物; 1 其中虚线表示键的存在或不存在,斜线表示α(向下)构型,实心三角形表示β(向上)构型; B是单键、双键或三键; n为0-6; X为CH 2 、S或O; Y为CO 2 H、CO 2 R、CONR 2 、CONHCH 2 CH 2 OH、CON(NHCH 2 CH 2 OH) 2 、CH 2 OR、P(O)(OR) 2 、CONRSO 2 R、SONR 2 或 2 R为H、C 1-6 烷基或C 2-6 烯基; R 2 和R 3 为C 1-6 线性烷基,可以相同也可以不同,并且可以相互连接以形成包含它们通常连接的碳的环; R 4 为氢、R、C(═O)R或在生理条件下易于去除的任何基团,使得R 4 有效地为氢; R 5 为氢或R; R 6 为 i) 氢; ii) 包含1至8个碳原子的线性或支链烃基,可以含有一个或多个双键或三键,或者所述烃基的氧或卤素衍生物,其中1-3个碳或氢原子可以被O或卤素取代;或 iii) 芳氧基、杂芳氧基、C 3-8 环烷氧基、C 3-8 环烷基、C 6-10 芳基或C 3-10 杂芳基,其中一个或多个碳被N、O或S取代;并且可以含有从卤素、三卤甲基、氰基、硝基、氨基、羟基、C 6-10 芳基、C 3-10 杂芳基、芳氧基、杂芳氧基、C 1-6 烷基、OR、SR和SO 2 R组成的取代基中选择的一个或多个取代基。 本发明的一些化合物及其制备方法也是新颖且非显而易见的。
  • 10,10-DIALKYL PROSTANOIC ACID DERIVATIVES AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE
    申请人:Allergan, Inc.
    公开号:US20040157901A1
    公开(公告)日:2004-08-12
    The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula I; 1 wherein the dashed line indicates the presence or absence of a bond, the hatched wedge indicates the &agr; (down) configuration, and the solid triangle indicates the &bgr; (up) configuration; B is a single, double, or triple covalent bond; n is 0-6; X is CH 2 , S or O; Y is any pharmaceutically acceptable salt of CO 2 H, or CO 2 R, CONR 2 , NHCH 2 CH 2 OH, N(CH 2 CH 2 OH) 2 , CH 2 OR, P(O)(OR) 2 , CONRSO 2 R, SONR 2 , or 2 R is H, C 1-6 alkyl or C 2-6 alkenyl; R 2 and R 3 are C 1-6 linear alkyl which may be the same or different, and may be bonded to each other such that they form a ring incorporating the carbon to which they are commonly attached; R 4 is hydrogen, R, C(═O)R, or any group that is easily removed under physiological conditions such that R 4 is effectively hydrogen; R 5 is hydrogen or R; R 6 is iv) hydrogen; v) a linear or branched hydrocarbon containing between 1 and 8 carbon atoms, which may contain one or more double or triple bonds, or oxygen or halogen derivatives of said hydrocarbon, wherein 1-3 carbon or hydrogen atoms may be substituted by O or a halogen; or vi) aryloxy, heteroaryloxy, C 3-8 cycloalkyloxy, C 3-8 cycloalkyl, C 6-10 aryl or C 3-10 heteroaryl, wherein one or more carbons is substituted with N, O, or S; and which may contain one or more substituents selected from the group consisting of halogen, trihalomethyl, cyano, nitro, amino, hydroxy, C 6-10 aryl, C 3-10 heteroaryl, aryloxy, heteroaryloxy, C 1-6 alkyl, OR, SR, and SO 2 R. Some of the compounds of the present invention and some of their methods of preparation are also novel an nonobvious.
    本发明提供了一种治疗眼压增高或青光眼的方法,包括向患有眼压增高或青光眼的动物施用一定治疗剂量的一种由通用式I表示的化合物; 1 其中虚线表示键的存在或不存在,斜线表示α(向下)构型,实心三角形表示β(向上)构型; B是单键,双键或三键; n为0-6; X为CH 2 ,S或O; Y为CO 2 H的任何药用可接受盐,或CO 2 R,CONR 2 ,NHCH 2 CH 2 OH,N(CH 2 CH 2 OH) 2 ,CH 2 OR,P(O)(OR) 2 ,CONRSO 2 R,SONR 2 ,或 2 R为H,C 1-6 烷基或C 2-6 烯基; R 2 和R 3 为C 1-6 线性烷基,可以相同也可以不同,并且可以相互连接以形成包含它们通常连接的碳的环; R 4 为氢,R,C(═O)R,或在生理条件下易于去除的任何基团,使得R 4 有效地为氢; R 5 为氢或R; R 6 为 iv)氢; v)含有1至8个碳原子的线性或支链烃,可以含有一个或多个双键或三键,或所述烃的氧或卤素衍生物,其中1-3个碳或氢原子可以被O或卤素取代;或 vi)芳氧基,杂芳氧基,C 3-8 环烷氧基,C 3-8 环烷基,C 6-10 芳基或C 3-10 杂芳基,其中一个或多个碳被N,O或S取代;并且可以含有从卤素,三卤甲基,氰基,硝基,氨基,羟基,C 6-10 芳基,C 3-10 杂芳基,芳氧基,杂芳氧基,C 1-6 烷基,OR,SR和SO 2 R组成的取代基中选择的一个或多个取代基。 本发明的一些化合物及其制备方法也是新颖且非显而易见的。
查看更多

同类化合物